Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -31.64% is 57% above its 5-year average of -73.51%, near the high end of its 5-year range (-158.49%–-25.89%).
2.51% below its 12-month average of -30.86%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -26.88%.
EBITDA MARGIN
-31.64%
EBITDA MARGIN AVG TTM
-30.86%
EBITDA MARGIN AVG 3Y
-44.02%
EBITDA MARGIN AVG 5Y
-73.51%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-2.51%
CURRENT VS 3Y AVG
+28.13%
CURRENT VS 5Y AVG
+56.96%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
PROCEPT BioRobotics Corporation
Market Cap
$983.77M
EBITDA Margin
-31.64%
TTM Avg
-30.86%
3Y Avg
-44.02%
5Y Avg
-73.51%
Market Cap
$981.54M
EBITDA Margin
-114.71%
TTM Avg
-284.80%
3Y Avg
-531.58%
5Y Avg
-445.59%
Market Cap
$978.33M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$971.97M
EBITDA Margin
17.12%
TTM Avg
8.95%
3Y Avg
16.20%
5Y Avg
17.02%
Market Cap
$995.99M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$967.94M
EBITDA Margin
-1113.67%
TTM Avg
-2254.05%
3Y Avg
-2254.05%
5Y Avg
-2254.05%
Market Cap
$1.01B
EBITDA Margin
-358.45%
TTM Avg
-358.45%
3Y Avg
-358.45%
5Y Avg
-358.45%
Market Cap
$949.90M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$949.84M
EBITDA Margin
-19083.66%
TTM Avg
-19083.66%
3Y Avg
-19083.66%
5Y Avg
-24221442.25%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PROCEPT BioRobotics Corporation (PRCT) | $983.77M | -31.64% | -30.86% | -44.02% | -73.51% |
| MeiraGTx Holdings plc (MGTX)vs › | $981.54M | -114.71% | -284.80% | -531.58% | -445.59% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $978.33M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $971.97M | 17.12% | 8.95% | 16.20% | 17.02% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $995.99M | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $967.94M | -1113.67% | -2254.05% | -2254.05% | -2254.05% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | -358.45% | -358.45% | -358.45% | -358.45% |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $949.90M | N/A | N/A | N/A | N/A |
| Savara Inc. (SVRA)vs › | $949.84M | -19083.66% | -19083.66% | -19083.66% | -24221442.25% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 8.03% | 9.94% | 10.00% | 10.00% |
Gross Margin
63.7%
EBITDA Margin
-31.6%
Operating Margin
-33.9%
Net Margin
-32.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -26.88% |
| 2026-03-31 | -37.13% |
| 2025-12-31 | -38.40% |
| 2025-09-30 | -25.89% |
| 2025-06-30 | -26.02% |
| 2025-03-31 | -37.54% |
| 2024-12-31 | -26.76% |
| 2024-09-30 | -36.15% |
| 2024-06-30 | -47.91% |
| 2024-03-31 | -59.42% |
| 2023-12-31 | -64.80% |
| 2023-09-30 | -69.95% |
| 2023-06-30 | -75.47% |
| 2023-03-31 | -113.03% |
| 2022-12-31 | -102.52% |
| 2022-09-30 | -105.17% |
| 2022-06-30 | -102.80% |
| 2022-03-31 | -105.28% |
| 2021-12-31 | -158.49% |
| 2021-09-30 | -138.45% |
| 2021-06-30 | -145.61% |
| 2021-03-31 | -145.01% |
| 2020-12-31 | -387.83% |
| 2020-09-30 | -487.09% |
| 2020-06-30 | -928.67% |
| 2020-03-31 | -928.67% |
